Table 1 Baseline characteristics and blood biomarkers of patients according to amyloid positivity on PET in Cohort 1 (KBASE-V) and Cohort 2 (Asan).

From: Comparison of plasma p-tau217 and p-tau181 in predicting amyloid positivity and prognosis among Korean memory clinic patients

 

Cohort 1 (KBASE-V)

Cohort 2 (Asan)

Aβ-negative

(n = 127)

Aβ-positive

(n = 71)

P

Aβ-negative

(n = 48)

Aβ-positive

(n = 52)

P

Demographics

 Age, years

67.6 ± 7.7

74.1 ± 7.6

< 0.001

71.5 ± 8.5

66.7 ± 10.4

0.013

 Sex, females (%)

69 (54.3)

43 (60.6)

0.396†

22 (45.8)

32 (61.5)

0.145†

 Education, years

10.1 ± 5.2

8.6 ± 4.7

0.041

11.6 ± 4.7

11.4 ± 4.8

0.789

Cognitive stage

  

< 0.001†

  

0.444†

 CU (%)

95 (74.8)

18 (25.4)

 

5 (10.4)

3 (5.8)

 

 MCI (%)

27 (21.3)

22 (31.0)

 

27 (56.3)

26 (50.0)

 

 Dementia (%)

5 (3.9)

31 (43.7)

 

16 (33.3)

23 (44.2)

 

Medical History

 Hypertension

58/125 (46.4)

29 (40.8)

0.452†

22 (45.8)

25 (48.1)

0.822†

 Diabetes mellitus

20 (15.7)

12 (16.9)

0.833†

22 (45.8)

10 (19.2)

0.004†

 Dyslipidemia

51/125 (41.1)

21 (29.6)

0.108†

19 (33.6)

26 (50.0)

0.296†

 Coronary artery disease

7 (5.5)

5 (7.0)

0.665†

7 (14.6)

7 (13.5)

0.872†

MMSE score, median (IQR)

26.0 (23.0–29.0)

21.0 (16.0–26.0)

< 0.001‡

25.0 (22.0–28.0)

23.0 (20.0–25.75)

0.035‡

CDR score, median (IQR)

0.0 (0.0–0.5)

0.5 (0.0–0.5)

< 0.001‡

0.0 (0.0–0.5)

0.5 (0.5–1.0)

0.466‡

CDR-SOB score, median (IQR)

0.0 (0.0–1.0)

1.5 (0.5–4.0)

< 0.001‡

2.0 (0.5–5.0)

3.0 (1.5–5.0)

0.249‡

Creatinine

0.81 ± 0.23

0.79 ± 0.26

0.604

0.87 ± 0.28

0.84 ± 0.18

0.585

APOE ε4 carrier

17 (13.4)

34 (47.9)

< 0.001

9 (18.8)

31 (59.6)

< 0.001†

Plasma p-tau181 (pg/mL)

2.14 ± 1.83

4.41 ± 2.42

< 0.001

2.30 ± 1.16

4.43 ± 1.82

< 0.001

Plasma p-tau217 (pg/mL)*

0.34 ± 0.29

1.38 ± 0.76

 < 0.001

0.41 ± 1.29

1.29 ± 0.77

< 0.001

  1. Data are presented as mean ± standard deviation or number (%) unless otherwise indicated.
  2. *Plasma p-tau217 was measured in 153 (77.3%) participants in cohort 1 and 97 (97%) in cohort 2.
  3. PET, positron emission tomography; KBASE-V, Korea Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer’s Disease; CU, cognitive unimpaired; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; IQR, interquartile range; CDR-SOB, Clinical Dementia Rating Scale sum of boxes.
  4. Student’s t-test, †Pearson’s chi-squared test, and the ‡Mann–Whitney U test were used.
Back to article page